low serum hepatitis b surface antigen level predicts compensated cirrhosis caused by chronic hepatitis b in hbeag positive patients in east china
نویسندگان
چکیده
conclusions in hbeag positive chb patients, low serum hbsag level is a useful predictor of compensated cirrhosis. objectives the aim of our study was to evaluate serum hbsag level as a biomarker for compensated cirrhosis in hepatitis b e antigen (hbeag) positive chb patients. patients and methods two-hundred and one hbeag-positive chinese chb patients with or without cirrhosis were enrolled in this retrospective study. cirrhosis was diagnosed based on liver biopsy. furthermore, patients with decompensated cirrhosis were excluded. a statistical analysis was performed regarding the association between serum hbsag level and compensated cirrhosis. results patients with compensated cirrhosis had a significantly lower mean serum hbsag level compared to those without cirrhosis (3.27 log10 iu/ml vs 4.17 log10 iu/ml, p < 0.001). furthermore, examining the correlation with compensated cirrhosis revealed that lower level of serum hbsag was a significant factor in multivariate analysis. the area under the receiver operating characteristics curve of serum hbsag was 0.856 for compensated cirrhosis. a positive predictive value of 66.2% and negative predictive value of 90.7% were obtained with a cut-off value of < 3.60 log10 iu/ml (4000 iu/ml) of serum hbsag. moreover, the rate of compensated cirrhosis increased to 75.0% after combining with apri > 2. backgrounds serum hepatitis b surface antigen (hbsag) levels are associated with fibrosis in patients with chronic hepatitis b (chb) infection.
منابع مشابه
Low Serum Hepatitis B Surface Antigen Level Predicts Compensated Cirrhosis Caused by Chronic Hepatitis B in HBeAg Positive Patients in East China
BACKGROUNDS Serum hepatitis B surface antigen (HBsAg) levels are associated with fibrosis in patients with chronic hepatitis B (CHB) infection. OBJECTIVES The aim of our study was to evaluate serum HBsAg level as a biomarker for compensated cirrhosis in hepatitis B e antigen (HBeAg) positive CHB patients. PATIENTS AND METHODS Two-hundred and one HBeAg-positive Chinese CHB patients with or w...
متن کاملSerum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B
BACKGROUND We investigated the differences in HBsAg kinetics at different levels of viremia in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB). METHODS We compared HBsAg levels among HBeAg-negative CHB patients with persistently undetectable HBV DNA (≤20 IU/mL; Group A, n = 100), HBV DNA 20-2,000 IU/mL (Group B, n = 100), and HBV DNA >2,000 IU/mL (Group C, n = 100). HBsAg and...
متن کاملSurface protein mutations in chronic hepatitis B patients who received hepatitis B vaccine therapy
Objective (s):The aim of this study was to determine the correlation between vaccine therapy and appearance of mutations in hepatitis B surface antigen (HBsAg)-positive chronic hepatitis B virus (HBV) patients. Materials and Methods: 16 patients received the HBV vaccine and another 16 individuals from the control group did not. The surface gene was amplified and directly sequenced from samples...
متن کاملEvaluation of miR-101 Level in Patients with Chronic Hepatitis B Virus Infection and Liver Cirrhosis
ABSTRACT Background and Objective: MiRNAs are small RNAs that are expressed in most eukaryotes, and can regulate gene expression by attaching to the 3’ end of target mRNA. MicroRNA-101 (miR-101) post-transcriptional regulation is important for host-virus interactions. In addition, miR-101 has a tumor suppressive role in liver cancer and metastasis, an...
متن کاملHepatitis B surface antigen seroconversion in HBeAg negative chronic hepatitis B patient during entecavir treatment.
Chronic hepatitis B (CHB) infection is still a huge public health problem despite the development of new drugs for its treatment, and complications of end-stage liver disease due to this infection results in one million deaths worldwide annually (1). The ideal end-point of therapy is hepatitis B surface antigen (HBsAg) loss with or without HBs seroconversion. However, it is frequently not achie...
متن کاملThe Study of Cerumen Hepatitis B Infection in Chronic Hepatitis B Patients by Real-Time PCR
Introduction: The hepatitis B is a viral infection that causes a big problem globally. About 2 billion people worldwide are infected and there are now about 400 million HBV-DNA carriers around the world. HBV infection is the ninth cause of death worldwide and infects about 350 million new cases each year in the world. HBV-DNA can be spotted in different body secretions and fluids, including se...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
hepatitis monthlyجلد ۱۵، شماره ۸، صفحات ۰-۰
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023